Weight, weight-loss medicines and your joints

A rheumatologist does not prescribe weight-loss medicines. They are prescribed by GPs, by specialist weight-management services and by private clinics, and nothing on this page is a way of obtaining one. So why cover them at all? Because weight has a real bearing on several rheumatological conditions, because a growing number of people with arthritis are already taking these medicines or considering them, and because starting one can affect your arthritis and its treatment. This guide is education about what weight and these medicines mean for your joints, not a recommendation to take one, and not a service the practice offers.

It is also worth saying plainly, and without judgement, that weight is not a moral failing and that carrying extra weight does not make joint pain your fault. Hormones, genetics, other medicines and circumstances all play a part. The aim here is practical: to help you understand the joint side of a decision made with your GP, and to make sure your rheumatology team is kept in the picture.

Weight affects the joints in two ways. The first is mechanical: every extra kilogram adds load to the knees and hips, multiplied several times over with each step, so losing excess weight is one of the most effective things a person with knee or hip osteoarthritis can do. The second is chemical: fat tissue is not inert padding but releases messengers that promote inflammation, which is why weight matters not only in wear-related arthritis but in inflammatory disease and gout too.

This guide does not re-teach the food and lifestyle side, because other guides own it. Diet and arthritis sets out what eating well can and cannot do, gout and diet covers urate, alcohol and the caution about crash dieting, and arthritis and exercise explains why movement helps and why it does not wear joints out. What follows is only the part those guides leave out: the medicines.

The newer weight-loss medicines are not all the same, and the differences matter.

GLP-1 receptor agonists are the group most people have heard of. Medicines such as semaglutide and liraglutide imitate a natural gut hormone released after eating, acting mainly on appetite and fullness so that you feel satisfied sooner and for longer, and slowing how quickly the stomach empties. Alongside a lower-calorie diet, people tend to eat less and lose weight.

Dual GIP and GLP-1 agonists add a second gut hormone. Tirzepatide acts on both the GLP-1 and the GIP receptors, and in practice this tends to produce more weight loss than a GLP-1 medicine alone. The principle is the same, appetite and fullness, but with two hormone signals rather than one.

Orlistat works in a completely different way. It does nothing to appetite; instead it blocks some of the enzymes that digest fat in the gut, so a portion of the fat in a meal passes through rather than being absorbed. It is an older medicine, generally produces more modest weight loss, and its effects on the bowel are why many people find it hard to persist with.

Weight-loss medicines also have a chequered history. Several earlier drugs were withdrawn once their risks emerged, including fenfluramine over heart-valve damage, sibutramine over cardiovascular risk and rimonabant over serious effects on mood. None is in use today, and the current medicines are different molecules with better-characterised safety, but the history is a reminder that these are serious medicines that belong under proper supervision.

How they are prescribed in the UK is changing quickly, so this guide keeps to the durable picture. They are obtained through a GP, a specialist weight-management service or a private clinic, and eligibility, the medicine offered and the funding all vary and are being revised as guidance evolves. For the current rules, your GP or a weight-management service is the up-to-date source.

For osteoarthritis of the knee and hip, the evidence for weight loss is about as clear as it gets. Losing excess weight reduces pain and improves how well the joint works, and UK guidance from NICE makes weight management, alongside exercise, a core part of treatment rather than an optional extra. The mechanism is intuitive: less weight means less load through a worn joint every time you move.

This is where the weight-loss medicines have their strongest arthritis evidence, largely borrowed from their effect on weight. A large trial reported in 2024 gave semaglutide to people with obesity and knee osteoarthritis and found meaningful weight loss together with a worthwhile reduction in knee pain and better function. It is an important result, fairly called a landmark. The honest reading, though, is that most of the benefit came through the weight loss itself rather than any separate action on the joint: the medicine helped the osteoarthritis by helping people lose weight, much as losing weight by other means would.

Weight matters a great deal in gout, and here there is a practical trap worth understanding before you start anything. Over the long term, losing excess weight lowers the urate level and reduces flares, so it is one of the most useful things a person with gout can do.

The catch is in the early weeks. Rapid weight loss, and starting a GLP-1 medicine in particular, can transiently push the urate level up and set off a gout flare in the first few months, before the longer-term benefit appears. This mirrors the caution in our gout and diet guide about crash dieting and fasting, which can trigger an attack for the same reason. It is not a reason to avoid losing weight, but it is a strong reason to lose it gradually rather than crash it, and to keep taking any urate-lowering treatment. If you have gout and start a weight-loss medicine, expect the first few months to be the riskiest for a flare, and agree a plan for managing one.

In inflammatory arthritis such as rheumatoid arthritis and psoriatic arthritis, weight plays a subtler role. Excess fat tissue is pro-inflammatory, and carrying too much weight is associated with higher disease activity and, for some treatments including certain biologics, a poorer response than would otherwise be expected. Losing excess weight can therefore improve disease control, which is a good reason to take it seriously within the wider plan.

Beyond that, honesty requires caution. There is early interest in whether the medicines themselves have a direct anti-inflammatory effect, over and above the benefit of losing weight, but this is observational and unproven. It would be wrong to present them as arthritis treatments or to imagine they can stand in for a disease-modifying medicine. The medicines that control the disease, such as methotrexate and the biologics and JAK inhibitors, remain the treatment; a weight-loss medicine, if you and your GP choose one, may help the general picture but does not replace them.

Like all effective medicines, these carry cautions, several particularly relevant if you have a rheumatological condition.

• Gut effects are the commonest. Nausea, and sometimes vomiting, constipation or diarrhoea, are frequent with the hormone medicines, especially early on; orlistat's effects are on the bowel. These can overlap with, or complicate, the side effects of arthritis medicines.
• Muscle as well as fat. Rapid weight loss tends to take some muscle with it, not only fat, so keeping active and maintaining strength matters, which is another reason arthritis and exercise is worth reading alongside this guide.
• Weight tends to return after stopping. These medicines work while they are taken; stop them and appetite and weight commonly return, so they are best thought of as a long-term commitment rather than a short course.
• Not in pregnancy or around conception. They are not used in pregnancy and are stopped before trying to conceive, an important point for anyone planning a family. Our guide to arthritis, autoimmune conditions and pregnancy covers arthritis and its treatment around pregnancy.
• Interactions with arthritis treatment are not fully studied. How these medicines interact with DMARDs and biologics has not been thoroughly researched. That is a reason not for alarm but for telling your rheumatology team if you start one, and keeping up your usual monitoring.

None of these rules a medicine in or out by itself; they are reasons to decide properly, with a prescriber who knows your history.

If there is one message to take from this guide, it is that where your arthritis is concerned a weight-loss medicine is not a decision to keep to yourself. Weight genuinely affects the joints, so losing excess weight may help your osteoarthritis, ease the long-term burden of gout and improve control of inflammatory disease. Yet the same change can nudge a gout flare in the early months, interact in ways not yet fully mapped with your arthritis medicines, and it does not, on current evidence, treat the arthritis itself. That is why the conversation is worth having in the open. Discuss the medicine with your GP or a weight-management service, who prescribe it and know the current rules; tell your rheumatology team, who can weigh what it means for your joints; and keep taking the medicines that control your arthritis. Managed that way, weight becomes one more thing you can work on sensibly, rather than one more thing to face alone.

Can I get a weight-loss medicine from my rheumatologist?

No. Rheumatologists do not prescribe weight-loss medicines. They are prescribed by GPs, specialist weight-management services or private clinics, and this guide exists to explain what weight and these medicines mean for your joints rather than to provide them. If you are considering one, that conversation belongs with your GP or a weight-management service. Do tell your rheumatology team if you start one, because it can affect your arthritis and its treatment.

Do weight-loss medicines treat arthritis?

Not directly, and it is worth being honest here. Where they help joints, it is mainly through weight loss itself, which genuinely eases load on the knees and hips and lowers urate in gout. Whether the medicines have any direct anti-inflammatory effect on arthritis is an early, unproven research question rather than an established fact. They are not a substitute for your arthritis treatment, such as DMARDs or biologics, which you should keep taking as prescribed.

I have gout. Could a weight-loss medicine set off a flare?

It can, at least at first, and this is worth knowing before you start. Losing weight lowers urate and reduces flares over the long term, but rapid weight loss, and the early weeks of a GLP-1 medicine, can transiently raise urate and trigger a gout flare, much as crash dieting can. This is not a reason to avoid losing weight, but it is a reason to do it gradually and to keep taking any urate-lowering treatment. Our gout and diet guide explains the crash-diet caution in more detail.

Will losing weight help my knee osteoarthritis?

Yes, this is one of the clearest messages in the whole field. For knee and hip osteoarthritis, losing excess weight reduces pain and improves how the joint works, and it is a core part of treatment in UK guidance. A large 2024 trial of semaglutide in people with obesity and knee osteoarthritis found meaningful weight loss and less pain, though the benefit came largely through the weight loss rather than any separate effect on the joint. Our guide to arthritis and exercise covers the movement side.

Can I take a weight-loss medicine while I am on methotrexate or a biologic?

This needs a proper conversation, because it has not been fully studied. There is limited research on how weight-loss medicines interact with arthritis treatments such as methotrexate or biologics, so tell your rheumatology team if you start one and keep up your usual monitoring. These medicines are also not safe in pregnancy or around conception, which matters for family planning; our guide to arthritis, autoimmune conditions and pregnancy covers that ground.